Market Overview:
The global live vaccines market is expected to grow at a CAGR of 9.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as rising incidence of infectious diseases, increasing demand for pediatric vaccines, and technological advancements in the vaccine industry. Based on type, the global live vaccines market is segmented into monovalent live vaccines and multivalent live vaccines. Monovalent live vaccines are further sub-segmented into bacterial and viral types. Bacterial type monovalent live vaccine includes Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococcal), Neisseria meningitidis (meningococcal) and others; while viral type monovalentlive vaccine includes human papillomavirus (HPV), rotavirus, varicella zoster virus (VZV) and others. Based on application, the global Live Vaccine Market is segmentedinto adultsand childrens segments .
Product Definition:
A live vaccine is a vaccine that uses a weakened or killed form of the virus, bacteria, or other pathogen to produce immunity. Live vaccines are created by altering the genes of the pathogen in order to weaken it.
Monovalent Live Vaccines:
Monovalent live vaccines are developed for a single disease and possess greater safety, stability & efficacy as compared to multivalent vaccines. The monovalent vaccine has been observed to be more immunogenic than the multivalent vaccine. Monovalent live vaccines have higher chances of inducing an immune response in the vaccinated individual as compared to multivalent vaccines which may lead to higher vaccination rates leading to successful disease prevention.
Multivalent Live Vaccines:
Multivalent live vaccines are attenuated viruses, which means they do not replicate in the body and thus cause no disease. They can be used to stimulate the immune system to respond more effectively against a virus. Multivalent live vaccines contain more than one type of antigen (body protein), which enables them to trigger the immune system's response in a variety of ways.
Application Insights:
Adults segment held the largest share of more than 50.0% in 2017. This is attributed to growing number of adults population that travels frequently for work or for leisure purposes which increases the risk of exposure to various diseases including measles, chickenpox, typhoid, cholera and hepatitis A & B. Moreover, increasing incidences of chronic diseases such as cancer and diabetes are expected to increase demand for immunization against these conditions among adults resulting in growth of this segment during the forecast period.
The children application segment is expected to witness significant growth over the forecast period owing to rising cases of vaccine-preventable diseases among infants and toddlers such as chickenpox, diphtheria, whooping cough (pertussis), measles.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers coupled with high R&D investment by companies is one of the major factors contributing to its largest share. In addition, increasing demand for immunization programs in this region is also expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness significant growth during the forecast period owing to rising awareness about vaccination programs among people as well as government support for immunization activities. Moreover, growing target population base along with rapid economic development will boost market size further on account of rising demand from developing countries such as China and India.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the major growth drivers for the live vaccines market. Infectious diseases are caused by pathogenic microorganisms, which can spread from person to person and cause serious health problems. The growing population and their close contact with each other has resulted in an increase in the number of cases of infectious diseases. This has led to an increased demand for live vaccines, which can protect people from these infections.
- Technological advancements: The development of new technologies has led to the introduction of novel live vaccines that offer better protection against infections. These technological advancements have helped in improving the efficacy and safety profile of live vaccines, thereby driving their demand worldwide.
- Growing awareness about vaccinations: There is a growing awareness among people about the importance vaccinations and their role in preventing various types of infections disease outbreaks globally Live vaccine manufacturers are focusing on educating people about vaccination through various marketing campaigns, which is likely to boost demand for these products in coming years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Live Vaccines Market Research Report
By Type
Monovalent Live Vaccines, Multivalent Live Vaccines
By Application
Adults, Children
By Companies
Merck, GlaxoSmithKline, Pfizer, Novartis, Astellas Pharma, Emergent BioSolutions, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Live Vaccines Market Report Segments:
The global Live Vaccines market is segmented on the basis of:
Types
Monovalent Live Vaccines, Multivalent Live Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- GlaxoSmithKline
- Pfizer
- Novartis
- Astellas Pharma
- Emergent BioSolutions
- AstraZeneca
Highlights of The Live Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monovalent Live Vaccines
- Multivalent Live Vaccines
- By Application:
- Adults
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Live Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Live vaccines are vaccines that are still alive after being injected into a person. They help the body build immunity to diseases by stimulating the body's immune system.
Some of the major companies in the live vaccines market are Merck, GlaxoSmithKline, Pfizer, Novartis, Astellas Pharma, Emergent BioSolutions, AstraZeneca.
The live vaccines market is expected to register a CAGR of 9.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Live Vaccines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Live Vaccines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Live Vaccines Market - Supply Chain
4.5. Global Live Vaccines Market Forecast
4.5.1. Live Vaccines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Live Vaccines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Live Vaccines Market Absolute $ Opportunity
5. Global Live Vaccines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Live Vaccines Market Size and Volume Forecast by Type
5.3.1. Monovalent Live Vaccines
5.3.2. Multivalent Live Vaccines
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Live Vaccines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Live Vaccines Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Live Vaccines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Live Vaccines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Live Vaccines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Live Vaccines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Live Vaccines Demand Share Forecast, 2019-2026
9. North America Live Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Live Vaccines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Live Vaccines Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Live Vaccines Market Size and Volume Forecast by Type
9.7.1. Monovalent Live Vaccines
9.7.2. Multivalent Live Vaccines
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Live Vaccines Demand Share Forecast, 2019-2026
10. Latin America Live Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Live Vaccines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Live Vaccines Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Live Vaccines Market Size and Volume Forecast by Type
10.7.1. Monovalent Live Vaccines
10.7.2. Multivalent Live Vaccines
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Live Vaccines Demand Share Forecast, 2019-2026
11. Europe Live Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Live Vaccines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Live Vaccines Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Live Vaccines Market Size and Volume Forecast by Type
11.7.1. Monovalent Live Vaccines
11.7.2. Multivalent Live Vaccines
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. B Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Live Vaccines Demand Share, 2019-2026
12. Asia Pacific Live Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Live Vaccines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Live Vaccines Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Live Vaccines Market Size and Volume Forecast by Type
12.7.1. Monovalent Live Vaccines
12.7.2. Multivalent Live Vaccines
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Live Vaccines Demand Share, 2019-2026
13. Middle East & Africa Live Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Live Vaccines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Live Vaccines Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Live Vaccines Market Size and Volume Forecast by Type
13.7.1. Monovalent Live Vaccines
13.7.2. Multivalent Live Vaccines
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Live Vaccines Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Live Vaccines Market: Market Share Analysis
14.2. Live Vaccines Distributors and Customers
14.3. Live Vaccines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Astellas Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Emergent BioSolutions
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AstraZeneca
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
